Epithelial – Mesenchymal Transition and StemCell Markers in Patients with HER 2-Positive Metastatic Breast Cancer

Currently, there is extensive information about circulating tumor cells (CTC) and their prognostic value; however, little is knownabout other characteristics of these cells. In thisprospective study,weassessed thegene transcripts of epithelial-to-mesenchymal transition—inducing transcription factors (EMT-TF) and cancer stem cell (CSC) features in patients with HER2þmetastatic breast cancer (MBC). Epithelial cells were enriched from peripheral blood mononuclear cells (PBMC) using antibody-coated anti-CD326 antibody (CD326þ) magnetic beads, and the residual CD326 PBMCswere further depleted of leukocytes using anti-CD45 antibody-coated magnetic beads (CD326 CD45 ). RNAwas extracted from all cell fractions, reverse transcribed to cDNA, and subjected to quantitative reverse transcription PCR to detect EMT-TFs (TWIST1, SNAIL1, ZEB1, and TG2) as a measure of CTCs undergoing EMT (EMT-CTCs). In addition, PBMCs were analyzed using multiparameter flow cytometry for ALDHactivity andCSCs that express CD24, CD44, andCD133. Twenty-eight patientswere included in this study. At least one EMT-TF mRNA was elevated in the CTCs of 88.2% of patients and in the CD326 CD45 cell fraction of 60.7% of patients. The CD326 CD45 fraction of patients with elevated SNAIL1 and ZEB1 transcripts also had a higher percentage of ALDHþ/CD133þ cells in their blood than did patients with normal SNAIL1 and ZEB1 expression (P 1⁄4 0.038). Our data indicate that patients with HER2þ MBCs have EMT-CTCs. Moreover, an enrichment of CSCs was found in CD326 CD45 cells. Additional studies are needed to determine whether EMT-CTCs and CSCs have prognostic value in patients with HER2þ MBCs treated with trastuzumab-based therapy. Mol Cancer Ther; 11(11); 2526–34. 2012 AACR.

[1]  G. van der Pluijm,et al.  Epithelial Plasticity, Cancer Stem Cells, and the Tumor-Supportive Stroma in Bladder Carcinoma , 2012, Molecular Cancer Research.

[2]  G. Hortobagyi,et al.  Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. , 2012 .

[3]  G. Hortobagyi,et al.  Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Hui Gao,et al.  Expression of epithelial–mesenchymal transition‐inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy , 2011, International journal of cancer.

[5]  Tanja Fehm,et al.  Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells , 2012, Breast Cancer Research.

[6]  D. Planchard,et al.  Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer , 2011, British Journal of Cancer.

[7]  W. Woodward,et al.  Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44⁺CD24lo cancer stem cell phenotype. , 2011, European Journal of Cancer.

[8]  Roberto Tagliaferri,et al.  Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients , 2011, Breast Cancer Research and Treatment.

[9]  Massimo Cristofanilli,et al.  Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment , 2011, Breast Cancer Research.

[10]  Andrew J Armstrong,et al.  Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers , 2011, Molecular Cancer Research.

[11]  B. Vincenzi,et al.  Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal , 2011, Journal of cellular and molecular medicine.

[12]  Paul A. Wiggins,et al.  Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state , 2011, Proceedings of the National Academy of Sciences.

[13]  Giuseppe Naso,et al.  Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients , 2011, Breast Cancer Research and Treatment.

[14]  Massimo Cristofanilli,et al.  Molecular mechanisms of metastasis in breast cancer—clinical applications , 2010, Nature Reviews Clinical Oncology.

[15]  X. Pivot,et al.  Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  G. Hortobagyi,et al.  Circulating Tumor Cells and Biomarkers: Implications for Personalized Targeted Treatments for Metastatic Breast Cancer , 2010, The breast journal.

[17]  M. Okada,et al.  [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[18]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[19]  Anne-Michelle Noone,et al.  Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Tanja Fehm,et al.  Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients , 2009, Breast Cancer Research.

[21]  Raghu Kalluri,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[22]  Sabine Kasimir-Bauer,et al.  Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies , 2009, Breast Cancer Research and Treatment.

[23]  F. Cardoso,et al.  Stemming Resistance to HER-2 Targeted Therapy , 2009, Journal of Mammary Gland Biology and Neoplasia.

[24]  Mieke Schutte,et al.  Anti-Epithelial Cell Adhesion Molecule Antibodies and the Detection of Circulating Normal-Like Breast Tumor Cells , 2009, Journal of the National Cancer Institute.

[25]  Kristine Broglio,et al.  Circulating tumor cells in metastatic breast cancer , 2008, Cancer.

[26]  M. Wicha,et al.  HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion , 2008, Oncogene.

[27]  A. Puisieux,et al.  Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition , 2008, PloS one.

[28]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[29]  A. Goldhirsch,et al.  Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  C. Heldin,et al.  Signaling networks guiding epithelial–mesenchymal transitions during embryogenesis and cancer progression , 2007, Cancer science.

[31]  G. T. Budd,et al.  Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival , 2006, Clinical Cancer Research.

[32]  Alison Stopeck,et al.  Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Jonathan W. Uhr,et al.  Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases , 2004, Clinical Cancer Research.

[34]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[35]  Jean Paul Thiery,et al.  Epithelial-mesenchymal transitions in development and pathologies. , 2003, Current opinion in cell biology.

[36]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Black Mm,et al.  Nuclear structure in cancer tissues. , 1957 .

[38]  A. Giordano,et al.  CTCs in metastatic breast cancer. , 2012, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[39]  Z. Gatalica,et al.  Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17 , 2011, Cancer.

[40]  G. van der Pluijm.  Epithelial plasticity, cancer stem cells and bone metastasis formation. , 2011, Bone.

[41]  Zang Ai-hua,et al.  Stem Cells,Cancer and Cancer Stem Cells , 2005 .

[42]  The world Health Organization Histological Typing of Breast Tumors--Second Edition. The World Organization. , 1982, American journal of clinical pathology.